Showing 2021-2030 of 7866 results for "".
Cutaneous Oncology
https://practicaldermatology.com/topics/skin-cancer-photoprotection/cutaneous-oncology/18638/Maui Derm Course Director George Martin, MD, recaps the discussion from the Cutaneous Oncology session during Maui Derm 2016. He shares his protocol for short-contact PDT therapy with an abbreviated incubation for reducing pain during treatment. Dr. Martin also offers an important clinical pearl forAn Off-Label Adjuvant Treatment for Melanoma
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermtube-journal-club-alam-part-2/18642/In part two of DermTube Journal Club Host Dr. Joshua Zeichner's interview with Murad Alam, MD, they talk about the role of imiquimod as an adjuvant therapy in treating melanoma. Dr. Alam describes how he uses imiquimod off-label after removing melanoma to help prevent recurrence. He also shares howPD Asks: The Future of Cosmetic Surgery
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/pd-asks-the-future-of-cosmetic-surgery/18680/PD Asks Joel Schlessinger, MD about the future of cosmetic dermatology. Watch Dr. Schlesinger discuss his views about how the speciality has evolved and grown with solid scientific research about treatments including fillers and toxins. He also discusses his meeting, Cosmetic Surgery Forum. Watch oGold Mettle: Dr. Michael Gold Talks Multifaceted Practice with Dr. Joel Cohen
https://practicaldermatology.com/topics/practice-management/gold-mettle-dr-michael-gold-talks-multifacted-practice-with-dr-joel-cohen/18868/Dr. Michael Gold's thriving Nashville practice includes a busy medical practice, a medical spa, and a research center. Plus, he's involved in teaching and educational ventures globally. How does he do it all—and stay on schedule? Dr. Joel L. Cohen finds out.Off-label Uses for Biologics
https://practicaldermatology.com/topics/psoriasis/off-label-uses-for-biologics/18964/Derm Insider Bonus Content: Host Neal Bhatia speaks with guests Alice Gottlieb, MD, Harold Farber, MD, and James Ulery, MD about various potential off-label uses for current and investigational systemic psoriasis therapies.Neotensil®: A Novel, Noninvasive Solution That Reduces the Appearance of Under-Eye Bags
https://practicaldermatology.com/topics/practice-management/neotensil-a-novel-noninvasive-solution-that-reduces-the-appearance-of-under-eye-bags/19058/Neotensil is the only noninvasive solution clinically proven to reduce the appearance of under-eye bags within an hour, with benefits that last up to 16 hours. Doris Day, MD, discusses the benefits of Neotensil, as well as patient selection, staff training and how to incorporate this unique and effeJoel Schlessinger MD Explains How a Spa Helped Build His Practice
https://practicaldermatology.com/topics/practice-management/joel-schlessinger-md-explains-how-a-spa-helped-build-his-practice-/19156/As the dermatology and skin care industry expands, the opportunity to offer new procedures, techniques and products for your patients grows. One way that Joel Schlessinger MD chose to advance his business was by adding a spa on to his current practice. In this video, he explains how the decision helHoya ConBio - Medlite Demo
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/hoya-conbio-medlite-demo/19460/Quick demo on the benefits on using Medlite and how it can improve your practice.Treatment Approaches for Psoriatic Arthritis
https://practicaldermatology.com/programs/practical-dermatology-il-17-journal-club/treatment-approaches-for-psoriatic-arthritis/48809/Naeim T. Issa, MD, PhD, FAAD, joins Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, to discuss the Mediterranean Journal of Rheumatology article “Emerging Targets in Psoriatic Arthritis: Dual IL-17A/F and Selective TYK2 Inhibition in a Clinical Perspective.”How does chronic AD histopathology evolve from spongiosis-dominant lesions to lichenified, fibrotic plaques?
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/how-does-chronic-ad-histopathology-evolve-from-spongiosis-dominant-lesions-to-lichenified-fibrotic-plaques/48772/Christopher Bunick, MD, FAAD, discusses the roles of the six major cytokines that drive atopic dermatitis pathophysiology: IL-4, IL-13, IL-31, TSLP, IL-22, and IFN-γ.